O

ver the last three years, John Flannery has transformed GE Healthcare.

He dragged a flat-lining business into the black. He reorganized staff to energize departments he thought had grown stagnant. He extended the company’s ability to support biologic drug manufacturing. And he poured more emphasis into emerging markets around the world.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Flannery is an accountant, you need a PhD scientist to be CEO of
    General Electric , like Jack Welch or Tom Vanderslice to drive innovation.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy